{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:52:02Z","timestamp":1769586722543,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.leukres.2009.04.017","type":"journal-article","created":{"date-parts":[[2009,5,16]],"date-time":"2009-05-16T04:16:47Z","timestamp":1242447407000},"page":"1459-1462","source":"Crossref","is-referenced-by-count":5,"title":["Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?"],"prefix":"10.1016","volume":"33","author":[{"given":"Moo-Kon","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Seop","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Mi","family":"Seol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Geun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goon-Jae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2009.04.017_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.04.017_bib2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.04.017_bib3","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib4","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdm343","article-title":"Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571)","volume":"18","author":"Agis","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2009.04.017_bib6","first-page":"152","article-title":"Chronic myeloid leukemia in 2006: a perspective","volume":"91","author":"Mauro","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2009.04.017_bib7","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib8","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1002\/cncr.20292","article-title":"Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase","volume":"100","author":"Cortes","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2009.04.017_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2003-05-1535","article-title":"Inhibitory effect of imatinib on normal progenitor cells in vitro","volume":"103","author":"Bartolovic","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib10","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2009.04.017_bib11","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2003-07-2575","article-title":"Molecular response to imatinib in late chronic-phase chronic myeloid leukemia","volume":"103","author":"Rosti","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","article-title":"Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2009.04.017_bib14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib15","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2009.04.017_bib16","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212609001945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T10:28:30Z","timestamp":1545215310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212609001945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0145212609001945"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2009.04.017","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}